SYMPOSIUM 3 – VACCINE AND VACCINE PROBLEMS

Prof. Annlies Wilder Smith and Dr. Ananda Amarasinghe co-chaired symposium 3 on Vaccines and Vaccine Problems.

Dr. Shibas Biswal, associate medical director at Takeda Vaccine in Singapore gave an overview on Takeda’s Dengue Vaccine Candidate. Takeda’s live attenuated tetravalent dengue vaccine candidate (TDV) contains a molecularly characterized dengue serotype 2 virus and three recombinant viruses expressing the pre membrane and envelope structural genes for serotype 1, 3 and 4 in the dengue serotype 2 virus genetic backbone.

Then Dr. Murga Vadivale, senior director, Dengue Medical Affairs Asia Pacific, Sanofi Pasteur in Singapore spoke on CYD TDV Vaccine Candidate Development. He mentioned that dengue vaccine is urgently needed as part of the integrated dengue prevention and control strategies in dengue endemic countries including Sri Lanka. The most advanced candidate is a tetravalent, live attenuated recombinant dengue vaccine (CYD TDV) from Sanofi Pasteur. The CYD TDV vaccine candidate has recently been approved for prevention of dengue in individuals 9 to 45 years of age living in endemic areas in Mexico, the Philippines, Brazil, and El Salvador; while two other candidates are close to enter into phase 3 efficacy trials.

Dr. Asitha De Silva, Professor in pharmacology at the Faculty of Medicine, University of Kelaniya spoke on vaccine clinical trials. He mentioned that more than half of under-five child deaths are due to diseases that are preventable and treatable through simple, affordable interventions. For some of the most deadly childhood diseases, such as Measles, polio, diphtheria, vaccines are available and can protect children from illness and death. However other infectious diseases like dengue, for which there is no specific treatment, continue to cause significant childhood morbidity and mortality. He also mentioned that since vaccines have a preventive role, the target population for vaccine is primarily healthy children and infants and therefore most of the vaccine studies are conducted in children.

SYMPOSIUM 4 – CONTROL STRATEGIES/NEW INTERVENTIONS IN DENGUE CONTROL

Prof. Scott O’Neill, Head of the “Eliminate Dengue” Research Program delivered his lecture on Wolbachia. Examining the potential use of inherited bacterial symbionts of insects known as ‘Wolbachia’ is a novel method to interfere with arbovirus transmission. This work has now progressed from basic bench studies into open field trials in five countries.

Dr. Jacob Kumaresan and Prf. Duane J. Gubler were moderators of this session. It was a round
table discussion with the participation of Prof. W. Abeyewickr-ame, Dr. Deepthi Perera, Dr. Kevin Goman, Dr. Rushika Perera and Prof. Scott O'Neill.

Prof. W. Abewickrama mentioned that their general objective is to establish an operational model to control dengue in Sri Lanka using multiple vector control intervention, new product development, community engagement and optimal use of existing technologies and tools.

Dr. Rushika Perera told that the biochemical environment in the Aedes aegypti mid gut is significantly changed upon virus infection and their studies have shown that these changes are required for the virus to replicate and disseminate from the mid gut. Given the capability of these vectors to various ecological conditions and their vectorial capacity for several arboviruses, it is hypothesized that vector metabolism has a significant impact on disease transmission, vector competence and insecticide resistance, and presents a novel avenue that should be explored for intervention.

SYMPOSIUM 5 – PATHOGENESIS AND DIAGNOSIS

Prof. Suchithra Nimmantiya and Dr. Dharshan De Silva co-chaired symposium 5 on Pathogenesis and Diagnosis.

Prof. Anavaj Sakuntabhai, who heads an internationally recognized research laboratory at the Institut Pasteur spoke on Asymptomatic dengue infection. He mentioned that the main objective of the DENFREE project is focus on finding key factors determining dengue transmission and dynamics in order to develop new tools and strategies for controlling dengue transmission.

Dr. Neelika Malavige, Director of the Center for Dengue Research, University of Sri Jayawardanapura gave an account on pathogenesis of severe dengue. Endothelial dysfunction which leads to increased vascular permeability is the hallmark of severe dengue (SD). SD is commoner in secondary infections and it is presumed that both cross reactive T cells and antibodies could be contributing to SD due to an aberrant immune response to dengue response.

Dr. Yie-Hoe Lee from Singapore spoke on ‘Are Cytokines Good Markers for Dengue Prognosis.’ Prognosis of dengue remains a challenge in allowing early, objective triage of patients with dengue fevers of differing severity. Because molecular signaling seemingly proceeds gross morphological or observable clinical symptoms, the potential use of biochemical signals such as immune modulators (cytokines, chemokines and growth factors) for early prognosis of severe dengue is specially welcoming. Systemic reviews suggest patients with severe dengue have higher frequencies of IL 10 level. IFN gamma was another probable prognostic marker.

Prof. Shmala Devi Sekaran talked on Dengue Diagnostics. Due to the absence of pathognomonic clinical features that can distinguish Dengue from other febrile illnesses, laboratory confirmation is an essential part in the diagnosis process. Diagnosis today in many countries is still based on serology though the detection of NS1 has slowly become incorporated. Dengue diagnosis is not only important for clinical management of patients, but also for epidemiological surveillance, outbreak intervention and vaccine development and monitoring.

The conference was successfully concluded after the closing session with the participation of Prof. Duane Gubler, Prof Annelies Wilder Smith, Dr. Paba Palihawadana and Dr. Hasitha Tissera.

Compiled by Dr. S.W.A. Rajika of the Epidemiology Unit
**Table 1: Selected notifiable diseases reported by Medical Officers of Health**

| Disease                  | A  | B  | C** | D** | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |
|--------------------------|----|----|-----|-----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| Dengue Fever             | A  | B  | C** | D** | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |
| Dysentry                 | A  | B  | C** | D** | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |
| Enteric Fever            | A  | B  | C** | D** | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |
| Encephalitis             | A  | B  | C** | D** | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |
| Leptospirosis            | A  | B  | C** | D** | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |
| Poliomyelis              | A  | B  | C** | D** | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |
| Typhus                   | A  | B  | C** | D** | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |
| Human Rabies             | A  | B  | C** | D** | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |
| Chickenpox               | A  | B  | C** | D** | E  | F  | G  | H  | I  | J  | K  | L  | M  | N  | O  | P  | Q  | R  |

**Note:**
- **A**: Cases reported during the current week
- **B**: Cumulative cases for the year
- **C**: Total number of reporting units
- **D**: Number of reporting units data provided for the current week
- **E**: Cumulative cases for the year
- **F**: Number of reporting units
- **G**: Typhus
- **H**: Human Rabies
- **I**: Chickenpox
- **J**: Leptospirosis
- **K**: Poliomyelis
- **L**: Typhus
- **M**: Human Rabies
- **N**: Chickenpox
- **O**: Leptospirosis
- **P**: Poliomyelis
- **Q**: Typhus
- **R**: Human Rabies
- **S**: Chickenpox
- **T**: Leptospirosis
- **U**: Poliomyelis
- **V**: Typhus
- **W**: Human Rabies
- **X**: Chickenpox
- **Y**: Leptospirosis
- **Z**: Poliomyelis

**Source:** Weekly Returns of Communicable Diseases (WRCD)

**Vol. 43 No. 18**

**23rd - 29th April 2016**

**SRILANKA**

**463 15502 39 832 1 74 10 249 10 397 58 1572 15 921 398 9 69 1715 21 424 11 425 75 93**
### Table 2: Vaccine-Preventable Diseases & AFP

<table>
<thead>
<tr>
<th>Disease</th>
<th>No. of Cases by Province</th>
<th>Number of cases during current week in 2016</th>
<th>Number of cases during same week in 2015</th>
<th>Total number of cases to date in 2016</th>
<th>Total number of cases to date in 2015</th>
<th>Difference between the number of cases to date in 2015 &amp; 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>W</td>
<td>C</td>
<td>S</td>
<td>N</td>
<td>E</td>
<td>NW</td>
</tr>
<tr>
<td><strong>AFP</strong></td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
</tr>
<tr>
<td><strong>Diphtheria</strong></td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
</tr>
<tr>
<td><strong>Mumps</strong></td>
<td>01</td>
<td>00</td>
<td>01</td>
<td>00</td>
<td>00</td>
<td>01</td>
</tr>
<tr>
<td><strong>Measles</strong></td>
<td>02</td>
<td>01</td>
<td>00</td>
<td>01</td>
<td>00</td>
<td>01</td>
</tr>
<tr>
<td><strong>Rubella</strong></td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
</tr>
<tr>
<td><strong>CRS</strong></td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
</tr>
<tr>
<td><strong>Tetanus</strong></td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
</tr>
<tr>
<td><strong>Neonatal Tetanus</strong></td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
</tr>
<tr>
<td><strong>Japanese Encephalitis</strong></td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
</tr>
<tr>
<td><strong>Whooping Cough</strong></td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
<td>00</td>
</tr>
<tr>
<td><strong>Tuberculosis</strong></td>
<td>77</td>
<td>19</td>
<td>19</td>
<td>10</td>
<td>13</td>
<td>09</td>
</tr>
</tbody>
</table>

**Key to Table 1 & 2**

- **Provinces:** W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.
- **Data Sources:**
  - Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps, Rubella, CRS.
  - Special Surveillance: AFP* (Acute Flaccid Paralysis), Japanese Encephalitis
  - CRS** = Congenital Rubella Syndrome
  - AFP and all clinically confirmed Vaccine Preventable Diseases except Tuberculosis and Mumps should be investigated by the MOH

**Dengue Prevention and Control Health Messages**

Look for plants such as bamboo, bohemia, rampe and banana in your surroundings and maintain them

**PRINTING OF THIS PUBLICATION IS FUNDED BY THE WORLD HEALTH ORGANIZATION (WHO).**

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@slt.net.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication.

**ON STATE SERVICE**

Dr. P. PALIHAWADANA
CHIEF EPIDEMIOLOGIST
EPIDEMIOLOGY UNIT
231, DE SARAM PLACE
COLOMBO 10